Research programme: urokinase plasminogen activator inhibitors - Dendreon

Drug Profile

Research programme: urokinase plasminogen activator inhibitors - Dendreon

Alternative Names: U-PA antagonists research programme - Dendreon; Urokinase plasminogen activator inhibitors research programme - Dendreon

Latest Information Update: 16 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dendreon Corporation
  • Class Monoclonal antibodies
  • Mechanism of Action Plasminogen activator inhibitor-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 05 Jan 2004 The activities of Dendreon San Diego LLC are being relocated to Dendreon's Seattle headquarters
  • 04 Aug 2003 Corvas International has been acquired by Dendreon Corporation and is now called Dendreon San Diego LLC
  • 12 Sep 2002 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top